Press Release

Zutphen, The Netherlands, 26 August 2010

Cryo-Save Group N.V.

Revenue up 5% to €19.5 million and Net Profit up 36% to €1.3 million in first half year 2010

Cryo-Save Group N.V. (Euronext: CRYO, 'Cryo-Save', or 'the Group'), Europe's leading adult stem cell storage bank, has published its interim results for the six months ended 30 June 2010.

Financial highlights

- Revenue up 5% to €19.5 million (1HY 2009: €18.6 million)
- EBITA* up 23% to €2.5 million (1HY 2009: €2.0 million)
- Operating profit up 31% to €1.9 million (1HY 2009: €1.4 million)
- Profit before taxation up 33% to €1.6 million (1HY 2009: €1.2 million)
- Net profit up 36% to €1.3 million (1HY 2009: €0.9 million)
- Basic earnings per share 13.7 euro cents (1HY 2009: 10 euro cents)
- Strong net cash from operating activities €2.0 million (1HY 2009: € 2.6 million)
- Solid cash position of €5.9 million as at 30 June 2010

* EBITA is defined as Earnings Before Interest, Taxation and Amortisation of identified intangible assets

Operational highlights

- Strengthened market position and product range in key markets
- Over 50% of new customers opted for combined service of cord blood and cord tissue storage in the countries where it is offered
- Successful European launch of Cryo-Lip®, a new product that allows the collection, processing and storage of adult stem cells from fatty tissue
- Volume growth of 13,300 samples
- Total number of samples stored: 135,000

Statement with respect to US court decision regarding embryonic stem cell research

Cryo-Save processes and stores adult stem cells collected from the umbilical cord blood and tissue immediately after birth and from fatty tissue from adults. Cryo-Save reconfirms that it is not involved in research, storage or expansion of embryonic stem cells. The court decision taken earlier this week in the United States relates to the temporary stop of government funding of embryonic stem cell research. This will not impact our business, on the contrary it should encourage the usage and potential of adult stem cells. Clinical trials and stem cell therapies use adult stem cells, embryonic stem cells are used for fundamental research.

Arnoud van Tulder, Chief Executive officer, commented:

"The first half of 2010 showed solid revenue and returns despite the economic environment which has affected some of our markets. A combination of tight cost control and the fact that we operate in a number of countries with an increasing range of products, has tempered the tougher conditions.

"We are very excited to be the first company in the world that offers adults the opportunity to store their stem cells from fatty tissue via Cryo-Lip®, further strengthening our product range.

"The strategic rationale for stem cell storage continues to grow as medical advances widen the potential uses for stored cells, whilst our geographical reach, product range and operational gearing enable us to maintain our leading position."

Enquiries:

Cryo-Save Group Arnoud van Tulder, Chief Executive Officer	**+ 31 (0) 575 548 998**
SPJ Financiële Communicatie (The Netherlands) Kees Jongsma/Leon Melens	**+31 (0)20 6478181**
Daniel Stewart & Company plc (UK) Chris Theis	**+ 44 (0) 20 7776 6550**
College Hill (UK) Adrian Duffield/Rozi Morris	**+ 44 (0) 20 7457 2020**

Free footage is available on www.videobankonline.com.

About Cryo-Save

With more than 135,000 samples saved, Cryo-Save is the leading stem cell bank in Europe and one of the fastest growing in the world. Driven by its international business strategy, Cryo-Save is now represented in 39 countries on three continents with state-of-the-art processing facilities in Belgium, Germany, Dubai, India and France.

Group Interim Report

Financial review

Revenue

Group revenue increased to €19.5 million (1HY 2009: €18.6 million), up 5%. This was achieved mainly as a result of a higher uptake of the combined service of cord blood and cord tissue storage.

The total storage of new samples was 13,300 samples. South Eastern Europe and India showed growth in volumes, whilst volumes decreased in some other countries as a result of the economic crisis, which has also reduced the number of births. The Group's relative market share remained stable and it strengthened its position as market leader, underpinned by the success of the combined storage of umbilical cord blood and cord tissue.

Geographical breakdown of revenue

€ in millions	**1 HY 2010**	**1 HY 2009**
Europe	18.4	17.8
Asia	0.7	0.5
Africa	0.4	0.3
Total	**19.5**	**18.6**

Europe remained Cryo-Save's main market. The growth in Asia was all organic, mainly from the Indian business.

Gross profit and gross margin

Gross profit increased to €13.4 million (1HY 2009: €13.2 million). The gross margin remained satisfactory at 69% (1HY 2009: 71%).

Operating expenses

Operating expenses, excluding depreciation and amortisation, amounted to €10.2 million (1HY 2009: €10.8 million), including €0.5 million incremental costs for the start up of the French activities and €0.2 million additional costs for the launch of Cryo-Lip®. These planned cost increases were partly offset by cost savings of around €0.4 million in the first half of 2010. The first half of 2009 was affected by a write-off of the receivable on the Arabian associate (€0.9 million).

€ in millions	**1 HY 2010**	**1 HY 2009**
Marketing and sales expenses	4.6	4.9
Research and development expenses	0.3	0.2
General and administrative expenses	5.3	5.7
Total	**10.2**	**10.8**

The decrease in marketing and sales expenses was mainly a result of lower costs of marketing materials as well as a reduction of staffing. This was partly offset by higher costs related to the launch of Cryo-Lip® and the French operations.

Half year 2009 research and development expenses were impacted by capitalisation of development expenses related to Cryo-Lip®, the Cryo-Save website and cord tissue service. There were no expenses that qualified for capitalisation in the first half of 2010. Research and development expenses also include a donation to Cell Therapy Research Institute, Lyon, France.

General and administrative expenses included incremental costs to accommodate the activities in France, mainly related to the processing and storage facility, and Cryo-Lip®.

EBITA and operating profit

EBITA was up 23% to €2.5 million (1HY 2009: €2.0 million). Higher revenue (€0.9 million) and gross profit (€0.2 million), and lower operating expenses (€1.3 million, including cost savings), were offset by further investments in the French operations (€0.5 million) and Cryo-Lip® (€0.2 million), and an increase of depreciation and amortisation (€0.3 million).

Operating profit amounted to €1.9 million, up 31% (1HY 2009: €1.4 million).

Depreciation was €0.6 million (1HY 2009: €0.4 million), and amortisation €0.7 million (1HY 2009: €0.6 million). The increase of depreciation was mainly caused by the full depreciation period regarding the Belgium and French building including its new equipment. Amortisation mainly increased due to the full amortisation period of the capitalised costs of cord tissue service and the Group's website.

Net finance costs/income

Net finance costs of €0.3 million increased from €0.2 million due to the full year impact of the interest payments on the sale and lease back agreement of the Belgium property.

Profit before taxation

Profit before taxation amounted to €1.6 million, up 33% (1HY 2009: €1.2 million).

Taxation

The effective tax rate (ETR) was estimated at 20% (1HY 2009: 22%) The ETR decreased compared to the first half of 2009 mainly due to fewer losses carried forward that were not capitalised due to the uncertainty of future profits to offset these losses. Furthermore, the effective tax rate decreased due to a higher share of taxable profits in countries with a relative low tax rate.

Profit for the period

Profit after taxation for the first half of 2010 was €1.3 million, up 36% (1HY 2009: €0.9 million).

Earnings per share

Basic earnings per share were 13.7 euro cents (1HY 2009: 10 euro cents).

Cash flow

Net cash from operating activities was €2.0 million (1HY 2009: €2.6 million). New European VAT legislation as of 1 January 2010 has resulted in significant domestic VAT receivables by foreign filers which has created a temporary delay in settling VAT positions. This has negatively affected Group's operational cash flow in the first half of 2010.
Moreover, Cryo-Save increased its shareholding of Sejtbank, Hungary and Cryo-Save Czech Republic from 70% to 100%, for a total cash consideration of €1.4 million.
Investments in property, plant and equipment of €1.7 million mainly related to the infrastructure of the French building and lab equipment for the French and Belgium facility.

Cryo-Save paid its dividend in June 2010 amounting to €0.5 million.

As at 30 June 2010, Cryo-Save had a cash position of €5.9 million (31 December 2009: €7.5 million).

Delisting

Cryo-Save was delisted from the AIM market of the London Stock Exchange with effect from 30 June 2010. Cryo-Save is now solely listed on the Euronext Amsterdam Stock Exchange.

Strategy

The Group has maintained its leading market position in all key markets and continues to achieve its strategic objectives: organic growth in existing markets, geographic growth into new markets, growth by acquisition and development of new services.

Operating review

Cryo-Save is Europe's leading stem cell bank with a market share of around 50%, having stored over 135,000 samples by the period ended 30 June 2010. The Group is present in almost all European countries, by means of its own subsidiary or via a marketing and sales partnership. No other stem cell bank matches Cryo-Save's geographic spread.

Cryo-Save announced the European launch of Cryo-Lip®, a new product that allows the collection, processing and storage of a rich mixture of adult stem cells from liposuction aspirate (fatty tissue that is normally discarded) in May 2010. A new cryopreservation process for fatty tissue has been developed and submitted for international patent by Cryo-Save.

In 2010 the Group continued its marketing and sales approach concentrating on customer acquisition through diagnostic centres and private clinics. Some contracts with leading private insurers that support this service towards their clients were signed or renewed.

Cryo-Save France prepared its response to the regulatory body Agence Française de Sécurité Sanitaire des Produits de Santé (Afssaps) after it had been informed that the authorisation for processing and storage of stem cells from the umbilical cord blood in France was refused, and started several court cases and indemnity procedures. Cryo-Save's quality control processes and state-of-the-art processing and storage facilities, licensed and compliant with the respective EU directives, guarantee its clients a strict safety profile and the highest quality products. Afssaps decision did not mention any quality related issues, but referred to legal restrictions in the French law related to stem cell storage and donation. Cryo-Save is confident that Afssaps will ultimately align its stem cell guidelines with those of the other EU countries. Cryo-Save therefore expects that the business impact will be temporary.

The main market for Cryo-Save in Asia is currently India. The Group has introduced its services successfully and the concept of banking umbilical cord blood and the cord tissue is expected to develop steadily across the country, particularly in the key metropolitan cities.

Cryo-Save acted quickly in April 2010 to minimize the transport disruption caused by the volcanic ash cloud by temporarily using road transport throughout Europe. Almost all samples were received in time, in compliance with Cryo-Save's standards, at its facilities for processing and storage. To handle all samples with the greatest care, the facilities were open 24 hours 7 days a week.

Applied research & development of new services

Following the completion of the EU funded project CRYSTAL, the European Commission Framework 7 has now funded and launched the HYPERLAB project. Cryo-Save is one of eight institutions which collaborate under the coordination of Prof. Dr. Heiko Zimmermann. This three year project, which was launched on 1 February 2010, aims to develop new and improved culture methods, media, and protocols for stem cell cultivation and differentiation.

Cryo-Save is the only cord blood bank in Europe to take part in these advanced projects, reflecting both its leading market position and its commitment to the development of stem cell research.

Current trading and outlook

Cryo-Save has strengthened its strategic position and product range. The combined service of cord blood and cord tissue storage has been well accepted by the market and has resulted in higher revenue. The new service Cryo-Lip® has been launched and the first samples are expected in the second half of 2010. Furthermore, Cryo-Save is constantly searching for new partners or acquisition opportunities in line with its strategy.

With the Group's geographic spread and the extended product range, the Board is confident that Cryo-Save will continue to maintain its leading position.

Related party transactions

In the first six months of 2010, no important transactions with related parties were made.

Principal risks and uncertainties

Pages 26-28 of Cryo-Save's Annual report 2009 include an extensive overview of the Group's principal risks and uncertainties, which are also applicable for the remaining six months of 2010.

Declaration of the Board of Executive Directors

The Board of Executive Directors declares that, as far as it is aware, the financial statements in this half year report, made up according to the applicable standards for financial statements, give a true and fair view of the equity, financial position and the results of the Group and its consolidated companies. The Board further declares that this report to the shareholders gives a true and fair view on the information that has to be contained therein.

Zutphen, the Netherlands, 26 August 2010

Arnoud van Tulder, Chief Executive Officer
Marc Waeterschoot, Executive Director

Condensed consolidated interim financial statements

These condensed consolidated interim financial statements are unaudited.

Condensed consolidated statement of income
in thousands of euro

For the six months ended 30 June

	Notes	2010	2009
Revenue	9	**19,534**	18,622
Cost of sales		**(6,121)**	(5,375)
Gross profit		**13,413**	13,247
Marketing and sales expenses		**4,638**	4,880
Research and development expenses		**294**	170
General and administrative expenses	10		
- Other general and administrative expenses		**6,615**	5,865
- Non-recurring write-down on equity accounted investees		**-**	907
Total operating expenses		**11,547**	11,822
Operating profit		**1,866**	1,425
Finance income		**31**	41
Finance costs		**(314)**	(276)
Net finance (costs)/income		**(283)**	(235)
Results relating to equity-accounted investees		**0**	0
Profit before taxation		**1,583**	1,190
Income tax expense	11	**321**	262
Profit for the period		**1,262**	928
Attributable to:			
- Equity holders of the Company		**1,262**	928
- Non-controlling interest		**-**	-
Profit for the period		**1,262**	928
Earnings per share (in euro cents)	12		
- Basic*		**13.7**	10.0
- Diluted*		**13.6**	10.0

* The comparative figures have been restated for the 5:1 share consolidation

Condensed consolidated statement of comprehensive income

in thousands of euro

For the six months ended 30 June	2010	2009
Profit for the period	**1,262**	928
Other comprehensive income		
Foreign currency translation differences	**117**	(76)
Other comprehensive income for the period	**117**	(76)
Total comprehensive income for the period	**1,379**	852
Attributable to:		
- Equity holders of the Company	**1,379**	852
- Non-controlling interest	**-**	-
Total comprehensive income for the period	**1,379**	852

Condensed consolidated statement of financial position

in thousands of euro

	Notes	30 June 2010	31 December 2009
Intangible assets		**33,888**	35,366
Property, plant and equipment		**14,947**	13,964
Investments in equity accounted investees		**0**	0
Deferred tax assets		**1,302**	1,121
Trade and other receivables		**871**	1,054
Total non-current assets		**51,008**	51,505
Inventories		**485**	251
Trade and other receivables		**8,710**	8,907
Current tax assets		**1,532**	687
Cash and cash equivalents		**5,937**	7,485
Total current assets		**16,664**	17,330
Total assets		**67,672**	68,835
Equity	13		
Issued share capital		**964**	964
Share premium reserve		**38,178**	38,178
Revaluation reserve		**620**	669
Legal reserve		**134**	134
Translation reserve		**(566)**	(683)
Treasury shares		**(3,277)**	(3,664)
Retained earnings		**8,754**	8,209
Equity attributable to equity holders of the Company		**44,807**	43,807
Non-controlling interest		**-**	-
Total equity		**44,807**	43,807
Liabilities			
Borrowings		**3,699**	3,795
Deferred revenue		**6,930**	6,090
Deferred considerations		**676**	2,080
Deferred tax liabilities		**2,502**	2,656
Other liabilities		**86**	84
Total non-current liabilities		**13,893**	14,705
Borrowings		**187**	180
Trade and other payables		**5,575**	6,533
Deferred revenue		**536**	471
Deferred considerations		**709**	1,264
Current tax liabilities		**1,965**	1,875
Total current liabilities		**8,972**	10,323
Total liabilities		**22,865**	25,028
Total equity and liabilities		**67,672**	68,835

Condensed consolidated statement of changes in equity

in thousands of euro

For the six months ended 30 June 2010

	Issued share capital	Treasury shares	Other reserves	Share-holders' equity	Non-controlling interest	Total equity
At 1 January 2010	**964**	**(3,664)**	**46,507**	**43,807**	**-**	**43,807**
Exchange differences on translating foreign operations	**-**	**-**	**117**	**117**	**-**	**117**
Net income recognized directly in equity	**-**	**-**	**117**	**117**	**-**	**117**
Profit for the period	**-**	**-**	**1,262**	**1,262**		**1,262**
Total recognized income and expense for the period	**-**		**1,379**	**1,379**	**-**	**1,379**
Share-based payments	**-**	**106**	**6**	**112**	**-**	**112**
Dividend distributed	**-**	**-**	**(554)**	**(554)**	**-**	**(554)**
Share options exercised	**-**	**281**	**(218)**	**63**	**-**	**63**
At 30 June 2010	**964**	**(3,277)**	**47,120**	**44,807**	**-**	**44,807**

For the six months ended 30 June 2009

	Issued share capital	Treasury shares	Other reserves	Share-holders' equity	Non-controlling interest	Total equity
At 1 January 2009	**964**	**(3,497)**	**45,586**	**43,053**	**-**	**43,053**
Exchange differences on translating foreign operations	-	-	(76)	(76)	-	(76)
Net income recognized directly in equity	-	-	(76)	(76)	-	(76)
Profit for the period	-	-	928	928		928
Total recognized income and expense for the period	-		852	852	-	852
Share-based payments	-	-	127	127	-	127
Dividend distributed	-	-	(462)	(462)	-	(462)
Repurchased shares	-	(106)	-	(106)	-	(106)
At 30 June 2009	**964**	**(3,603)**	**46,103**	**43,464**	**-**	**43,464**

Condensed consolidated statement of cash flows

in thousands of euro

For the six months ended 30 June

	2010	2009
Cash flows from operating activities		
Profit for the period	**1,262**	928
Adjustments for:		
Income tax expense	**321**	262
Finance costs	**314**	276
Finance income	**(31)**	(41)
Depreciation and amortisation	**1,360**	1,051
Equity settled share-based payment transactions	**112**	127
	3,338	2,603
Organic movements in working capital		
(Increase)/decrease in (non)current trade and other receivables	**380**	185
(Increase)/decrease in inventories	**(234)**	(31)
(Increase)/decrease (non)current tax assets	**(963)**	408
Increase/(decrease) in (non)current liabilities	**185**	214
Increase/(decrease) in current tax liabilities	**(178)**	(16)
Net cash from operations	**2,528**	3,363
Interest paid	**(289)**	(113)
Interest received	**31**	41
Income taxes paid	**(270)**	(705)
Net cash from operating activities	**2,000**	2,586
Cash flows from investing activities		
Net acquisition spending	**(1,400)**	-
Purchase of property, plant and equipment	**(1,736)**	(2,296)
Purchase of intangible assets	**(61)**	(164)
Disposals of non-current assets	**134**	81
Net cash (used in)/generated by investing activities	**(3,063)**	(2,379)
Cash flows from financing activities		
Share options exercised	**63**	-
Repurchase of own shares	**-**	(106)
Dividend distributed	**(471)**	-
Redemption of borrowings	**(89)**	(58)
Proceeds from borrowings	**-**	4,200
Net cash generated by/(used in) financing activities	**(497)**	4,036
Net increase/(decrease) in cash and cash equivalents	**(1,560)**	4,243
Cash and cash equivalents at 1 January	**7,485**	4,697
Exchange differences	**12**	13
Cash and cash equivalents at 30 June	**5,937**	8,953

Notes to the condensed consolidated interim financial statements 2010

(in thousands of euro, unless indicated otherwise)

1. Reporting entity

Cryo-Save Group N.V. (the 'Company', or 'the Group') is a limited liability company domiciled in The Netherlands. The address of its registered office and principal place of business is IJsselkade 8, 7201 HB Zutphen, The Netherlands.

2. Basis of preparation

Statement of compliance

The Group's condensed consolidated interim financial statements as at and for the six months ended 30 June 2010 were approved for publication by the Board of Directors on 25 August 2010.

The condensed consolidated interim financial statements of the Company as at and for the six months ended 30 June 2010 have been prepared in accordance with IAS 34 Interim Financial Reporting. As permitted by IAS 34, these statements do not include all of the information required for full annual financial statements, and should be read in conjunction with the consolidated financial statements of the Company as at and for the year ended 31 December 2009. In addition, the notes to the condensed consolidated interim financial statements are presented in a condensed format.

For further details on the principle accounting policies of the Company, we refer to our website, www.cryo-savegroup.com, Investor Relations.

3. Significant accounting policies

The significant accounting policies applied by the Group in these condensed consolidated interim financial statements are the same as those applied by the Group in its consolidated financial statements as at and for the year ended 31 December 2009, except for the adoption of the following standards, amendments to standards and interpretations, which have been adopted as relevant to the Group for the first time:

Accounting for business combinations
As of 1 January 2010, the Group applied IFRS 3 'Business Combinations' (revised standard 2008) in accounting for business combinations. The revised standard has been applied prospectively and since there were no significant acquisitions during the first half of 2010, the change did not have a material impact on the Company's consolidated financial statements.

Other IFRS standards and interpretations effective from 1 January 2010 did not have a material impact on the Group.

4. Change in accounting estimates

In the first six months of 2010 the Group did not change any accounting estimate, which materially impacted the reported figures.

5. Use of estimates and judgements

The preparation of interim financial statements requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates. Estimated and underlying assumptions are reviewed on an ongoing basis. Revision to accounting estimates are recognized in the period in which the estimate is revised and in any future periods affected.

In preparing these condensed consolidated interim financial statements, the significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those applied to the consolidated financial statements as at and for the year ended 31 December 2009.

6. Seasonality

The interim operations of the Company are not impacted by seasonal or cyclical patterns.

7. Acquisitions

At 25 February 2010, the Company acquired the remaining 30% minority shareholding of its Hungarian subsidiary Sejtbank Egeszegugyi Szolgaltato Korlatolt Felelossegu ('Sejtbank') and Cryo-Save CZ s.r.o. (formerly Archiv Bunek s.r.o.), for a total cash consideration of €1.4 million.

8. Operating segments

The Group identified two operating segments: the extraction and storage of adult human stem cells, and other types of products and services. The latter mainly consists of Output Pharma Services GmbH ('Output').

There are no material levels of integration between the two reportable segments. The accounting policies of the reportable segments are the same, except for revenue recognition. Information regarding the results of each reportable segment is included below. Performance is measured based on EBITA (earnings before interest, tax and amortisation of identified intangible assets), as included in the internal management reports that are reviewed by the Board. There are no inter-segment transactions. Corporate overhead costs were not allocated to the segment 'other', but to the segment 'stem cell storage'.

Information about reportable segments

for the six months ended 30 June	Stem cell storage		Other		Total	
	2010	2009	**2010**	2009	**2010**	2009
Revenue						
Segment revenue	**18,911**	18,012	**623**	610	**19,534**	18,622
Other segment information						
EBITA	**2,447**	1,897	**44**	136	**2,491**	2,033
Finance income	**30**	36	**1**	5	**31**	41
Finance expense	**(314)**	(276)	**0**	0	**(314)**	(276)
Depreciation and amortisation	**(1,352)**	(1,041)	**(8)**	(10)	**(1,360)**	(1,051)
Profit before taxation	**1,538**	1,050	**45**	140	**1,583**	1,190
Income tax expense	**308**	224	**13**	38	**321**	262
Segment assets	**67,251**	70,891	**421**	623	**67,672**	71,514
Segment liabilities	**22,573**	27,830	**292**	220	**22,865**	28,050
Capital expenditure	**1,795**	2,457	**2**	3	**1,797**	2,460

Revenue from external customers attributed to the Company's country of domicile, The Netherlands, amounted to €0.2 million (1HY 2009: €0.2 million).

Revenue included €94,000 interest related to customer payment in instalments (1HY 2009: €46,000). Interest is charged against several interest rates applicable in the countries.

Geographical information
In presenting information on the basis of geographical information, revenue per continent is based on the geographical location of customers. Non-current assets, other than financial instruments and deferred tax assets, are based on the geographical location of the assets.

for the six months ended 30 June	Revenue		Non-current assets	
	2010	2009	**2010**	2009
Europe	**18,386**	17,800	**48,006**	50,510
Asia	**696**	504	**828**	756
Africa	**452**	318	**1**	2
	19,534	18,622	**48,835**	51,268

9. Revenue

for the six months ended 30 June		
	2010	2009
Stem cell extraction and storage	**18,911**	18,012
Other products and services	**623**	610
Total revenue	**19,534**	18,622

10. Depreciation and amortisation expenses

for the six months ended 30 June

	2010	2009
Depreciation of property, plant and equipment	**619**	424
Amortisation of identified intangible assets	**625**	608
Amortisation of other intangible assets	**116**	19
Total depreciation and amortisation expenses	**1,360**	1,051

The increase of depreciation expenses is due to the full year impact of depreciation of the two new processing and storage facilities in Belgium and France. The increase of amortisation expenses of other intangible assets is due to the amortisation of development costs of the website and the two launched services Cord Tissue and Cryo-Lip® during the first half year of 2010.

11. Taxation

Income tax expense reported for the six month period ended 30 June 2010 is recognized based on management's best estimate of the weighted average annual effective income tax rate for the full financial year, applied to the pre-tax income of the interim period. The Group's applied consolidated effective tax rate for the six months ended 30 June 2010 was 20% (for the year ended 31 December 2009: 24.2%; for the six months ended 30 June 2009: 22%).

Estimates and judgement by management are required in determining the Group’s deferred tax liabilities, amongst others corporate income tax and value added tax (VAT). The calculation of the tax liabilities is partly based on the interpretations of applicable tax laws in the jurisdictions in which the Group operates. Although the Group believes the tax estimates are reasonable, there is no assurance that the final determination of the tax liabilities will not be materially different from what is reflected in the statement of income and balance sheet. Should additional taxes be assessed these could have a material effect on the Group’s results of operation or financial condition.

12. Earnings per share

for the six months ended 30 June

	2010	2009
Basic earnings per share (in euro cents)	**13.7**	10.0
Diluted earnings per share (in euro cents)	**13.6**	10.0

Basic earnings per share (EPS) are calculated by dividing profit attributable to ordinary equity holders of the Company by the weighted average number of ordinary shares outstanding during the period.

The calculation of diluted earnings per share is based on the calculation of the basic earnings per share, adjusted to allow for the assumed conversion of all dilutive share options.

The average market value of ordinary shares during the first half year of 2010 did exceed the exercise price of the options granted in 2009. Hence, these options had a minor dilutive effect. The average market value of ordinary shares during the first half of 2010 did not exceed the exercise price of the options granted in 2007: £11.05, 2008: £10.50, and 2010: €5.81 respectively, hence these options had no dilutive effect.

Reconciliation between number of shares and weighted average number of shares:

for the six months ended 30 June

	2010	2009
Issued ordinary shares at 1 January	**9,639,191**	48,195,986
Effect of share consolidation	**-**	(38,556,795)
Shares held in treasury	**(412,389)**	(357,688)
Weighted average number of shares	**9,226,802**	9,281,503

Reconciliation between weighted average number of shares and diluted weighted average number of shares:

for the six months ended 30 June

	2010	2009
Weighted average number of shares	**9,226,802**	9,281,503
Share options	**26,586**	-
Diluted weighted average number of shares	**9,253,388**	9,281,503
Profit attributable to ordinary equity holders of the Company	**1,262**	928

13. Share options, treasury shares and dividend

Share options
At 28 April 2010, the Company has granted 54,000 ordinary shares to staff of the Company, at an exercise price of €5.81 per share.

The fair market value of each conditionally awarded share was €2.78, as determined by an outside consulting firm. The fair value of services received in return for share options granted is based on the fair value of share options granted, measured using a binomial model.

Treasury shares
To cover the dilutive effect of the granted share options in 2007, 2008, 2009 and 2010 under the 2007 and 2009 Share Option Scheme to staff and to fund acquisitions, the Group started a share buyback programme in 2007. During the first half year of 2010 the Company reissued 27,500 own shares in treasury, resulting in 396,500 own shares held in treasury at 30 June 2010. Treasury shares are recorded at cost, representing the market price on the acquisition date.

Dividend
Following the shareholder resolution on 19 May 2010, the Company paid a dividend of 6 euro cent per share amounting to €554,000 for the year ended 31 December 2009.

14. Contingent liabilities or contingent assets

In the first half of 2010, there were no material changes to the Group's commitments and contingent liabilities from those disclosed in the Annual Report for the year ended 31 December 2009.

15. Events after the reporting period

Court case Cryo-Save France SAS

Cryo-Save France SAS has started a court case against Agence Française de Sécurité Sanitaire des Produits de Santé (Afssaps) after it was informed in May 2010 that the authorization for processing and storage of stem cells from the umbilical cord blood in France was refused. At the same time Cryo-Save started an indemnification procedure against the Ministry of Health, who is accountable for Afssaps' decisions. The business impact is expected to be temporary and not significant.

Egyptian partner

Cryo-Save signed a contract with a new agent for Egypt, Vacsave for Medical Services, further expanding its business to the Middle East North Africa (MENA) region. Egypt, with 90 million inhabitants and almost 1 million births per year, is an attractive market for Cryo-Save. It will focus initially on the two largest metropolitans Cairo and Alexandria. Some small private banks are already present, whilst public banking is not offered.

Appointment of liquidity provider

Cryo-Save appointed Kempen & Co as liquidity provider as of 2 August 2010, aiming to enhance the liquidity of its shares on Euronext Amsterdam.

Contact details
Cryo-Save Group N.V.
IJsselkade 8
7201 HB Zutphen
The Netherlands
Tel. +31 (0)575 54 89 98
Fax +31 (0)575 50 91 16

For more information on Cryo-Save visit
www.cryo-savegroup.com, or contact Investor Relations
at ir@cryo-save.com